Record Q2 product sales and robust royalty growth drove a 4% revenue increase and a 42% operating margin, with strong Buvidal and Brixadi performance. 2026 guidance is reaffirmed, and key regulatory and pipeline milestones are anticipated in the second half.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.